Bli medlem
Bli medlem

Du är här

2017-02-01

Bactiguard Holding AB (publ): Bactiguard expands in the Middle East

Bactiguard signs distribution agreement and enters partnership with
Heal Pharma for Egypt. The product registration has been initiated
and market launch is planned for the second quarter of 2017.

"Egypt is the most populous country in the Arab world, with major
challenges in the healthcare sector. We are convinced that
Bactiguard's portfolio of products and services for reducing hospital
acquired infections, combined with our partner's extensive network
and competence, will make this market one of our biggest in the
region in a few years", says Christian Kinch, CEO.

"We are excited about the partnership with Bactiguard. Their
innovative technology meets an obvious need in the Egyptian market,
where one of biggest challenges is serious infections in combination
with extensive use of antibiotics. By offering a solution that
prevents infections, we can increase patient safety and reduce the
use of antibiotics as well as hospitalization time and, thereby,
increase the efficiency of the healthcare system", says Dr Mohamed
Khalifa, Chairman of Heal Pharma.

Egypt is the most populous country in North Africa and the Middle
East, with a population of approximately 90 million. Heal Pharma,
based in Cairo, has a nationwide reach and was established in 2008 by
Dr Mohamed Khalifa.

The agreement was signed in the presence of the Swedish Ambassador to
the United Arab Emirates, Jan Thesleff, and Niclas Jacobson from the
Swedish Ministry of Social Affairs at Arab Health in Dubai. For the
tenth year in a row, Bactiguard participates with its own personnel
and a booth at this annual international trade exhibition.

For further information, please contact:

Cecilia Edström, SVP Sales & New business, cell phone: +46 72 226 23
28

About Bactiguard

Bactiguard is a Swedish medtech company with a global presence,
offering a solution that prevents healthcare associated infections
caused by medical devices. By preventing infections, we contribute to
a reduced use of antibiotics and the spread of multi-resistant
bacteria, which is a growing problem worldwide. We save lives,
increase patient safety and significantly reduce the cost for the
healthcare and society. Our technology is well-proven, safe and
tissue friendly and consist of a thin layer of noble metals that
prevents bacterial growth. The coating can be applied on almost all
medical devices. Bactiguard-coated urinary catheters are market
leading in the US and Japan and the company has also its own product
portfolio consisting of Foley catheters, central venous catheters and
endotracheal tubes. Bactiguard is a growth company, focused on
markets in Europe, Middle East, Asia and Latin America. The company
has about 60 employees worldwide, mainly at the headquarters in
Stockholm and the production facility in Malaysia and is listed on
Nasdaq Stockholm. Read more about Bactiguard at www.bactiguard.com

-----------------------------------------------------------
http://news.cision.com/bactiguard-holding-ab--publ-/r/bactiguard-expands...
http://mb.cision.com/Main/9686/2177805/621839.pdf

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.